Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)

BACKGROUND: Esophagogastric adenocarcinoma (EGA) presents a substantial global health challenge as the number of cases continues to rise. The current standard approach for treating localized EGA involves a combination of triplet chemotherapy, which consists of a platinum compound, a fluoropyrimidine...

Descripción completa

Detalles Bibliográficos
Autores principales: Tintelnot, Joseph, Stein, Alexander, Al-Batran, Salah-Eddin, Ettrich, Thomas, Götze, Thorsten, Grün, Barbara, Haag, Georg Martin, Heuer, Vera, Hofheinz, Ralf-Dieter, Homann, Nils, Bröring, Tobias Sebastian, Cruz, Mariana Santos, Kurreck, Annika, Lorenzen, Sylvie, Moosmann, Nicolas, Müller, Christian, Schuler, Markus, Siegler, Gabriele, Binder, Mascha, Gökkurt, Eray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615128/
https://www.ncbi.nlm.nih.gov/pubmed/37909020
http://dx.doi.org/10.3389/fonc.2023.1272175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615128/
https://www.ncbi.nlm.nih.gov/pubmed/37909020
http://dx.doi.org/10.3389/fonc.2023.1272175

Ejemplares similares